Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

716
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
716
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The TFAM-OGG1 axis mediates T-2 toxin-induced chondrocyte mitochondrial dysfunction and cartilage degeneration.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2026
Same author

The emergence of the language system in the toddler brain.

bioRxiv : the preprint server for biology·2026
Same author

Antifungal Properties and Genomic Analysis of <i>Burkholderia pyrrocinia</i> DLL-114, an Endophyte of Camphor Tree.

Plant disease·2026
Same author

Functional Magnetic Resonance Imaging in Awake Infants: Insights From More Than 750 Scanning Sessions.

Infancy : the official journal of the International Society on Infant Studies·2026
Same author

Targeting sorting nexin 3 to treat pulmonary fibrosis by dual modulating Wnt/β-catenin signaling.

Cell death & disease·2026
Same author

Latent class analysis of quality of life among patients with Kashin-Beck disease and its association with health literacy and social support.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2025

Related Experiment Video

Updated: Sep 9, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K

Cardiac Dual-Targeting Nanocatalysts for Heart Failure Therapy by Breaking the ROS-Inflammation Positive Feedback.

Haoyu Du1,2, Dinghu Ma1,2, Xiaoyuan Zhang1,2

  • 1Huiya Hospital of The First Affiliated Hospital of Sun Yat-sen University, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Huizhou, 516081, P. R. China.

Advanced Healthcare Materials
|September 5, 2025
PubMed
Summary
This summary is machine-generated.

This study introduces FUTA, a novel dual-target nanocatalyst for heart failure (HF). FUTA demonstrates potent antioxidant and immunomodulatory effects, improving cardiac function and reducing fibrosis in HF models.

Keywords:
heart failure targetingimmunomodulationmagnetic nanocatalystoxidative stress scavengingtannic acid functionalization

More Related Videos

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.0K

Related Experiment Videos

Last Updated: Sep 9, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.6K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.0K

Area of Science:

  • Biomaterials Science
  • Cardiovascular Research
  • Nanomedicine

Background:

  • Heart failure (HF) presents a global health challenge, driven by oxidative stress and immune imbalance.
  • Current HF therapies lack cardiac specificity, limiting efficacy due to rapid heart perfusion.
  • Developing targeted strategies is crucial for effective HF treatment.

Purpose of the Study:

  • To develop a dual-target nanocatalyst (FUTA) for enhanced heart failure treatment.
  • To investigate FUTA's antioxidant and immunomodulatory capabilities in vitro and in vivo.
  • To evaluate FUTA's therapeutic potential in improving cardiac structure and function.

Main Methods:

  • Functionalization of Fe3O4@UiO-66 with tannic acid (TA) to create FUTA.
  • In vitro assessment of FUTA's radical scavenging and ROS-mitigating properties.
  • In vivo evaluation of FUTA's cardiac targeting, antioxidant effects, and impact on cardiac function and fibrosis using magnetic attraction and TA-ECM binding.

Main Results:

  • FUTA exhibited potent free radical and reactive oxygen species (ROS) scavenging in vitro.
  • FUTA restored mitochondrial membrane potential and reduced cardiomyocyte hypertrophy in vitro.
  • In vivo studies showed selective FUTA accumulation in injured myocardium, leading to improved cardiac structure, function, and reduced fibrosis.

Conclusions:

  • FUTA demonstrates significant therapeutic potential for heart failure.
  • The nanocatalyst effectively targets cardiac tissue and exerts synergistic antioxidant and immunomodulatory effects.
  • FUTA offers a promising material-based strategy for heart failure treatment by regulating metabolic and immune pathways.